Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Grantham Mayo Van Otterloo & Co. LLC

Grantham Mayo Van Otterloo & Co. LLC grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 140.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,093,866 shares of the medical research company's stock after acquiring an additional 639,467 shares during the quarter. Thermo Fisher Scientific comprises approximately 1.9% of Grantham Mayo Van Otterloo & Co. LLC's holdings, making the stock its 20th largest holding. Grantham Mayo Van Otterloo & Co. LLC owned 0.29% of Thermo Fisher Scientific worth $569,062,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Legacy Investment Solutions LLC bought a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at approximately $26,000. Barrett & Company Inc. bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $28,000. FPC Investment Advisory Inc. bought a new position in Thermo Fisher Scientific during the fourth quarter valued at $28,000. Missouri Trust & Investment Co purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $29,000. Finally, Pillar Financial Advisors LLC purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter worth about $29,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on TMO. UBS Group raised their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a research note on Friday, January 31st. Royal Bank of Canada set a $693.00 price objective on Thermo Fisher Scientific in a research report on Friday, January 31st. Wells Fargo & Company boosted their target price on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. StockNews.com raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, January 14th. Finally, Citigroup dropped their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $647.09.

Remove Ads

Thermo Fisher Scientific Stock Down 6.2 %

Shares of NYSE TMO traded down $27.95 during trading hours on Thursday, hitting $425.60. 1,896,501 shares of the stock were exchanged, compared to its average volume of 1,682,303. The company has a market cap of $160.56 billion, a PE ratio of 25.74, a PEG ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific Inc. has a 12 month low of $409.85 and a 12 month high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The firm has a fifty day moving average price of $516.75 and a 200-day moving average price of $541.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.41%.

Insiders Place Their Bets

In related news, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares of the company's stock, valued at $5,759,736.32. This represents a 25.87 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the sale, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. This represents a 7.99 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 23,900 shares of company stock valued at $13,106,062. Insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.